Related Experiment Video
Updated: Aug 10, 2025
09:53
An In Vitro Model for Studying Cellular Transformation by Kaposi Sarcoma Herpesvirus
Published on: August 25, 2017
8.4K
Ozanimod-Associated Iatrogenic Kaposi Sarcoma in a Patient With Ulcerative Colitis
Sarah Sandlow1, Puja Rai2, Ann Shum2
1Tufts University, Medford, MA.
ACG Case Reports Journal
|February 15, 2023
Summary
Ozanimod effectively treats ulcerative colitis but may increase malignancy risk. A rare case of Kaposi sarcoma in the skin and colon developed after ozanimod treatment, highlighting the need for physician awareness.
Area of Science:
- Immunology
- Gastroenterology
- Dermatology
Background:
- Ozanimod is an oral sphingosine-1-phosphate receptor modulator used for ulcerative colitis.
- While effective, there are concerns regarding potential malignancy risks associated with its use.
Observation:
- A patient with biologic-resistant ulcerative colitis was treated with ozanimod.
- The patient developed biopsy-proven Kaposi sarcoma affecting both the skin and colon.
Findings:
- This case represents a rare instance of Kaposi sarcoma occurring shortly after initiating ozanimod therapy (2 months).
- The development of malignancy in both cutaneous and colonic sites is a unique presentation.
Implications:
- Physicians should consider the potential for rare malignancies, such as Kaposi sarcoma, in patients treated with ozanimod.
- Increased vigilance and awareness are crucial for identifying adverse events associated with this immunomodulatory agent.
Related Concept Videos
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
226
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
226
01:29Drugs for Treatment of Ulcerative Colitis in IBD
209
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
209
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
180
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
180
01:27Inflammatory Bowel Disease I: Ulcerative Colitis
265
Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
265
01:29Inflammatory Bowel Disease IV: Pharmacological Management
169
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
169
01:30Inflammatory Bowel Disease II: Crohn's Disease
331
Introduction
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
331